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Breast cancer is one of the most commonly diagnosed types of cancer among women. 
Breast cancer mortality rates remain high probably because its diagnosis is hampered 
by inaccurate detection methods. Since changes in protein expression as well as mod-
ifications in protein glycosylation have been frequently reported in cancer development, 
the aim of this work was to study the differential expression as well as modifications of 
glycosylation of proteins from plasma of women with breast cancer at different stages of 
disease (n = 30) compared to healthy women (n = 10). A proteomics approach was used 
that depleted albumin and IgG from plasma followed by glycoprotein enrichment using 
immobilized Moraceae lectin (frutalin)-affinity chromatography and data-independent 
label-free mass spectrometric analysis. Data are available via ProteomeXchange with 
identifier PXD003106. As result, 57,016 peptides and 4,175 proteins among all samples 
were identified. From this, 40 proteins present in unbound (PI—proteins that did not 
interact with lectin) and bound (PII—proteins that interacted with lectin) fractions were 
differentially expressed. High levels of apolipoprotein A-II were detected here that were 
elevated significantly in the early and advanced stages of the disease. Apolipoprotein 
C-III was detected in both fractions, and its level was increased slightly in the PI frac-
tion of patients with early-stage breast cancer and expressed at higher levels in the PII 
fraction of patients with early and intermediate stages. Clusterin was present at higher 
levels in both fractions of patients with early and intermediate stages of breast cancer. 
Our findings reveal a correlation between alterations in protein glycosylation, lipid metab-
olism, and the progression of breast cancer.
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inTrODUcTiOn
Breast cancer is a clinically and biologically heterogeneous 
disease. The disease exhibits distinctive and complementary 
characteristics, which may induce tumor growth and metastatic 
dissemination, such as sustaining proliferative signaling, evading 
growth suppressors, activating invasion and metastasis, enabling 
replicative immortality, inducing angiogenesis, and resisting cell 
death (1, 2). Breast cancer represented one of the most commonly 
diagnosed types of cancer among women in 2015. Moreover, 
breast cancer is expected to account for 29% (231,840) of all new 
cancers of women (3).
The causes of breast cancer are unknown, and risk factors 
are limited primarily to females, increasing age, family history, 
early menarche, late menopause, pregnancy at an advanced 
age, and prolonged hormone replacement therapy (4). The 
frequent discovery of disease in the early stage allows effec-
tive treatment that facilitates a cure. Mammography, which 
is commonly used due to its ability to detect early forms of 
breast cancer, allows implementation of various treatment 
options. Moreover, mammography is still used for screening a 
population, although it is far from perfect. For example, out of 
100 women with breast cancer, approximately 10% will not be 
diagnosed (5). Nowadays, digital breast tomosynthesis (DBT) 
is being proposed as an alternative for conventional mammog-
raphy for breast cancer screening. It reduces and/or eliminates 
overlapping obscuring breast tissue. Although there are some 
disadvantages with DBT, this relatively lost-cost technology 
may be used effectively in the screening and diagnostic settings 
actually (6).
The increasing interest in discovering biomarkers reflects 
the requirement for developing highly sensitive and specific 
clinical tests for diagnosis and prognosis. Biomarkers can 
assist in the staging of several tumors, although reliable breast 
cancer markers are insufficient to provide precise diagnosis or 
classification. At least 1,000 proteins are potential biomarkers 
for cancer, but few are approved by the United States Food 
and Drug Administration (7). Some are glycoproteins, which 
are applied to analyzing different types of cancer (8, 9). The 
changes of protein expression as well as modifications such as 
glycosylation are frequently reported to contribute to cancer 
development, and these findings have stimulated research 
designed to develop new proteomic strategies to identify sero-
logical indicators of cancer based on different approaches to 
analyze protein glycosylation (10).
Because changes in protein glycosylation are associated with 
diseases such as cancer and immune disorders, a common strat-
egy of glycoproteomics is using lectins as a selection tool, mainly 
because they bind glycoproteins present in complex mixtures. 
Lectins are defined as proteins of non-immune origin that are 
present in animals, plants, and microorganisms and bind specifi-
cally and reversibly to carbohydrates or glycoconjugates (11–13). 
Studies using plant lectins in biotechnology reveal the presence 
of highly diverse anomalous and truncated glycans in cancer 
cells. Further, the antitumor effects provoked by plant lectins are 
attributed to their ability to bind reversibly to epitopes that seem 
to arise during tumorigenesis (14–16).
Qualitative and quantitative analyses of plasma proteins 
from healthy women and women with breast cancer are pre-
sented here. We depleted plasma of albumin and IgG and then 
enriched for glycoproteins using Moraceae lectin (frutalin)-
affinity chromatography and data-independent (MSE) label-free 
mass spectrometry to identify proteins that were differentially 
expressed as a function of disease stage. The goal of the present 
study was to identify differentially expressed proteins and 
changes in glycosylation patterns, in order to contribute the 
development of a protein profile that suggests an association 
with the development and characterization of breast cancer at 
different stages.
MaTerials anD MeThODs
We analyzed plasma samples from healthy women and women 
with one of three different stages of ductal breast cancer. The 
Ethics Committee of the Hospital Geral de Fortaleza approved 
this study (protocol number 050507/10). Blood samples were 
used after obtaining a patient’s written informed consent, and the 
study was designed and conducted in accordance with the ethical 
principles for medical research involving human subjects stated 
in the Declaration of Helsinki.
study Patients
A total of 40 patients had a mean age of 52.3 ± 11.7 years (case 
group) and 46.3 ±  14.3  years (control group). These patients 
were enrolled in our prospective study based on a series of 10 
healthy controls and 30 patients diagnosed with ductal infiltrative 
carcinoma of the breast from May 2011 to June 2012 attending 
in the General Hospital of Fortaleza, Brazil. Women with newly 
diagnosed clinical and anatomopathological ductal breast cancer 
clinical staging (CS) I, II, and III without metastasis and other 
associated neoplasms, whose tumors were biopsied and diagnosed 
as breast cancer at the Biopsy Laboratory of the Hospital Geral de 
Fortaleza, were eligible for the case group (n = 10, each stage). 
Patients with breast cancer with associated malignancies, prior 
treatment, and a Karnofsky Index >70 (17) were excluded from 
the case group. The control group (n =  10) comprised healthy 
women, without a diagnosis of cancer. Women with chronic or 
transmitted diseases, receiving pharmacologic therapy, those 
with neurological or psychiatric disorders, alcoholics, smokers, 
or those whose data records were incomplete regarding the 
characteristics required for the study were excluded as well. 
Clinicopathological data from patients were acquired by a team 
of researchers at analysis of medical records and included age at 
diagnosis, weight, clinical and family history, menopausal status, 
CS, and characteristics of the tumor and showed no significant 
differences (Tables 1–3).
Blood samples
Blood sample from all subjects were processed identically as 
follows: samples were collected by venipuncture into tubes 
containing a separating gel clot activator and were centrifuged at 
1,300 × g at 4°C for 20 min. The plasma was removed, transferred 
in 1-ml aliquots to polypropylene tubes, and stored at −80°C.
TaBle 3 | Description of the case group according to the characteristics 
of the tumor.
Tumor characteristics n %
subtype
Ductal 30 100
Lobular 0 0
clinical staging
0 0 0
I 10 33.33
II 10 33.33
III 10 33.33
IV 0 0
size
Tis 0 0.0
T1 (until 2 cm) 11 36.7
T2 (2–5 cm) 7 23.3
T3 (≥5 cm) 5 16.7
T4 5 16.7
No data 2 6.7
lymph nodes committed
N− 19 63.3
N+ 9 30
No data 2 6.6
histopathological grade
1 4 13.3
2 7 23.3
3 8 26.7
No data 11 36.7
TaBle 2 | Description of the clinical profile of women in study.
clinical profile case group (n = 30) control (n = 10) χ2
Weight 67.5 ± 11.2 65.7 ± 11.1 p = 0.264
Menopause status
Pré-menopause 14 04 p = 0.286
Pós-menopause 16 06
nulliparity
Yes 05 02 p = 0.796
No 25 08
Breast-feeding
Yes 23 07 p = 0.881
No 02 01
Tobacco smoking
Yes 14 07 p = 0.338
Ex-smoker 11 03
No 04 0
Family history
Yes 21 06 p = 0.850
No 09 04
Difference between the groups was evaluated chi-squared test (χ2) with level 
significance of p < 0.05.
TaBle 1 | Description of the socioeconomic profile of women in study.
sociodemographic data case group (n = 30) control (n = 10) χ2
Marital status
Married 17 07 p = 0.006
Single 07 02
Othersa 06 01
ethnicity
White 07 03 p = 0.12
Brown 18 06
Othersb 05 01
education (years of study)
≤9 years 12 07 p = 0.94
10–12 years 08 03
≥12 years 10 0
Family incomec
≤1 MS 21 04 p = 0.72
2–6 MS 07 06
≥10 MS 02 0
aDivorced, widow, and others.
bYellow, black, and indigenous.
cMinimum salary value (MS): equivalent to $300. Difference between the groups was evaluated chi-squared test (χ2) with level significance of p < 0.05.
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isolation of an α-d-galactose lectin-
ligand from Artocarpus incisa (frutalin) 
seeds
The α-d-galactose lectin-ligand frutalin was purified according to 
a published protocol (18). Seeds of A. incisa were collected in the 
state of Ceara, Brazil, and ground to a fine powder, delipidated in 
N-hexane, then suspended (1:10 w/v) in 0.15 M NaCl with agita-
tion for 1 h at room temperature. The suspension was centrifuged 
at 10,000 × g for 30 min at 4°C, and the supernatant was passed 
through filter paper and applied to a d-galactose-agarose column 
equilibrated with 0.15 M NaCl. The non-retained peak was eluted 
with the same equilibration buffer until the absorbance at 280 nm 
reached 0.020. The retained peak containing frutalin was eluted 
with 0.2  M d-galactose in 0.15  M NaCl, dialyzed exhaustively 
against distilled water, and lyophilized.
immobilization of Frutalin on  
sepharose 4B
The purified frutalin was immobilized on a Sepharose 4B resin acti-
vated with cyanogen bromide (GE Healthcare, Buckinghamshire, 
UK). Lectin was incubated in the presence of its inhibitor sugar 
4Lobo et al. Stage-Specific Protein Expression in Breast Cancer
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(0.2  M d-galactose) with the resin preactivated in an alkaline 
environment. All procedures followed the instructions provided 
by the manufacturer (GE Healthcare).
immunodepletion
Albumins and IgGs were removed from plasma to enrich for less 
abundant proteins. Aliquots of plasma were filtered through a 
0.22-mM membrane (VertipurePVDF syringe filters, Vertical), 
then applied to a HiTrap Albumin and IgG Depletion column 
(GE Healthcare) attached to an ÄKTApurifier 10 fast protein 
liquid chromatography (FPLC) system (GE Healthcare). Plasma 
(150 µl) was applied to the column, which was pre-equilibrated 
with a solution of 20-mM Tris–HCl, pH 7.4, 0.15 M NaCl. The 
non-retained material was stored at −80°C. Albumin and IgG 
were eluted with 0.1 M glycine–HCl buffer, pH 2.7, delivered at 
1 ml/min, and absorbance was monitored at 216 and 280 nm.
normalization of samples and  
Frutalin-affinity chromatography
The depleted peaks were quantified by their absorb-
ance at 280  nm using a NanoVue Plus Spectrometer (GE 
Healthcare). Four pools (control, breast cancer stages I, II, 
and III) were formed based on the same protein concentra-
tion and were subjected to frutalin-affinity chromatography 
using an ÄKTApurifier 10 FPLC system (GE Healthcare). 
Chromatography was performed at 1 ml/min, and the absorb-
ance of the eluate was monitored at 216 and 280 nm. All runs 
were performed using 1 ml of the depleted pooled plasma. The 
frutalin-affinity column was pre-equilibrated and washed with 
a solution of 20-mM Tris–HCl, pH 7.4, 0.15 M NaCl. After col-
lecting the non-retained material (unbound-PI fraction), the 
retained peak (bound-PII fraction) was eluted with d-galactose 
in 0.2 M Tris–HCl 20 mM, pH 7 4, 0.15 M NaCl. Both fractions 
were dialyzed against ultrapure water and concentrated using 
centrifugal concentrators with molecular mass cutoff values of 
5 kDa (VivaSpin, GE Healthcare).
nanoUPlc and label-Free  
Data-independent Mass  
spectrometric analysis
The unbound-PI and bound-PII fractions from healthy women 
and those with breast cancer were dialyzed, concentrated, and 
quantified using a Nanovue Spectrometer (GE Healthcare) 
according to the absorbance at 280 nm. Samples were adjusted 
to the same protein concentration, dried, and digested with 
trypsin as described below. Each pooled sample (100 µg) was 
denatured, digested with trypsin, and analyzed using mass 
spectrometry. The samples were diluted in 50-mM ammonium 
bicarbonate, denatured in the presence of 0.2% RapiGEST SF at 
80°C for 15 min in a dry bath (Waters, Milford, USA), reduced 
with 100-mM dithiothreitol at 60°C for 60 min, then alkylated 
with 300-mM iodoacetamide for 30 min in the dark at room 
temperature. The samples were digested with a modified trypsin 
(Promega) at a ratio of enzyme:protein = 1:100 (w/w) at 37°C 
and incubated overnight. The reaction was stopped using 10 µl 
of 5% trifluoroacetic acid, mixed, incubated for 90 min at 37°C, 
centrifuged, and the supernatant was transferred to a Waters 
Total Recovery vial (Waters). Tryptic peptides of yeast alcohol 
dehydrogenase (ADH) were added to a final concentration of 
50  fmol/μl as an internal standard to estimate the amount of 
each sample injected into the column for absolute quantifica-
tion (19). The final protein concentration was approximately 
1 µg/µl.
Tryptic peptides were separated using a nanoACQUITY 
UPLC system (Waters) equipped with an HSS T3 C18 reverse-
phase column (1.8  µm, 75  µm ×  20  mm) for 110  min using a 
0–40% gradient (see below) for 90 min, 40–85% for 5 min, then 
the column was re-equilibrated for 15  min at 35°C. The flow 
rate was 0.35 µl/min, and the mobile phases A and B contained 
0.1% formic acid in water and 0.1% formic acid in acetonitrile, 
respectively. All samples were injected at least in triplicate. Data-
independent analysis (MSE) of tryptic peptides was performed 
using a Synapt HDMS mass spectrometer (nanoESI-Qq-oaTOF) 
(Waters, Manchester, UK). The instrument was operated in 
electrospray positive-ion mode nanoESI (+) and in “V” mode 
with a precursor double-charge resolution ≥10,000 full width at 
half maximum. The mass spectrometer data were acquired using 
a NanoLockSpray probe channel infusion of Glu–Fib (Glu1) 
derived from fibrinopeptide B human (M + 2H)2+ = 785.2486, 
and the MS/MS Glu–Fib fragments were used for final calibration 
of the instrument. All analyses were performed using a Glu–Fib 
mass channel at 30-s intervals.
The exact mass retention times (20) of nanoLC-MSE data were 
collected with alternative lower (3  eV) and elevated collision 
ramp energies (15–50 eV) applied to the argon collision cell using 
a scan time of 1.5 s with a 0.2-s interscan delay for each MS scan 
from m/z 50 to 2,000. The RF offset (MS profiles) was adjusted 
such that LC/MS data were effectively acquired from m/z 300 to 
2,000, which ensured that any mass observed in the LC/MSE data 
<m/z 300 arose from dissociations in the collision cell.
Data Processing, Protein identification, 
and Quantification
LC/MSE data were processed and proteins were identified 
using ProteinLynxGlobalServer v.2.4 software (PLGS) with 
the UNIPROT (2014_09) reverse Homo sapiens annotated 
database. For searching spectra and the database, we used the 
default parameters of PLGS followed by a maximum of one 
missed trypsin-cleavage, a fixed carbamidomethyl modification 
and a variable oxidation modification (20, 21). The absolute 
quantification of each run was calculated according to the 
three most intense peptides (label-free Hi3 method) using 
ADH peptides as internal standards (21). Further, for relative 
quantification of identified proteins from each expression 
group, we selected an internal common housekeeping protein 
alpha-1-antichymotrypsin [UNIPROT (AACT_HUMAN)] 
and alpha-1-antitrypsin (A1AT_HUMAN) for normalizing 
expression levels, which was performed using PLGS ExpressionE 
software (Waters, UK) (22). The average quantitative values of 
all samples were calculated, and the p value (p < 0.05) calculated 
using ExpressionE software to refer to the differences between 
biological replicates.
FigUre 1 | representative chromatogram of a depleted plasma 
sample prepared using affinity chromatography on an immobilized 
Frutalin column attached to an fast protein liquid chromatography 
system ÄKTapurifier 10 (ge healthcare). Chromatography was 
performed at a constant flow of 1 ml/min and absorbance was monitored at 
216 nm. The column was washed with a solution of 20 mM Tris–HCl, pH 7.4, 
0.15 M NaCl. The non-retained peak (Unbound-PI fraction) was collected, 
and the bound material (retained peak, Bound-PII fraction) was eluted using 
d-galactose in a solution of 0.2 M Tris–HCl 20 mM, pH 7 4, 0.15 M NaCl.
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resUlTs
A representative chromatogram of a depleted plasma sample 
prepared using affinity chromatography on an immobilized 
Frutalin column showing the unbound-PI and bound-PI 
fractions prepared from each group of subjects is illustrated 
in Figure 1. The analysis identified 57,016 peptides among all 
samples and replicates. This number of peptides corresponded 
to proteins that were consistently identified that corresponded to 
87% of all proteins. These peptides were identified with accuracy 
as a normal distribution, a maximum ±  10  ppm, and a false 
discovery rate (FDR) = 0.3 (Figure 2A). Eleven percent of the 
doubly or triply charged peptides were produced by in-source 
fragmentation, whereas missed cleavages accounted for 11% 
(Figure 2B). The analysis identified 4,175 reproducible proteins 
with an average of 14 peptides per protein, and among them, 
2,622 and 2,106 proteins were identified in the unbound-PI 
(FDR = 0.3%) and bound-PII (FDR = 0.2%) fractions, respec-
tively. There was a 1,000-fold range of the concentrations of 
the quantified proteins (Figure 3). Qualitative analysis did not 
reveal proteins unique to a group’s fractions in three of three 
biological replicates.
After identification and absolute quantitation of the proteins 
of each run using yeast ADH (UNIPROT: P00330) as the inter-
nal standard, alpha-1-antichymotrypsin (UNIPROT: P01011) 
and alpha-1-antitrypsin (UNIPROT: P01009) were selected as 
housekeeping proteins to normalize expression levels and per-
form label-free relative quantification of proteins present in the 
unbound-PI and bound-PII fractions, respectively. The criterion 
for selecting housekeeping proteins was as follows: proteins 
detected in all runs under all conditions with the lowest coef-
ficient of variance according to the quantitative counts for their 
respective Hi3 peptides.
Proteins were identified that were present at different levels in 
plasma samples from patients with stages I, II, and III breast can-
cer compared with those of healthy controls. Only proteins with 
differential expression [breast cancer:control with absolute ratios 
>1.5 (upregulated) and <0.66 (downregulated)] were considered. 
The levels of the remaining proteins with ratios between 1.5 and 
0.66 were considered unchanged. The criteria stated above were 
met by 102 and 94 proteins in each of three biological replicates in 
the unbound-PI and bound-PII fractions, respectively. The breast 
cancer:control unbound-PI fraction comprised 14 upregulated 
and 1 downregulated proteins, and the bound-PII fraction com-
prised 10 upregulated and 15 downregulated proteins for each 
stage of the disease. Among these up or downregulated proteins, 
some of them were chosen for discussion and are shown in 
Tables 4 and 5.
Figure 4 summarizes the ratios of the levels of proteins in the 
unbound-PI (A) and bound-PII (B) fractions from the plasma of 
breast cancer patients according to disease stage compared with 
those of healthy controls.
DiscUssiOn
Although human plasma may represent an attractive, readily 
accessible source for biomarker discovery and is a more repro-
ducible sample than serum, it presents technical challenges for 
MS-based proteomic analysis owing to its complexity and large 
dynamic range of protein concentrations (23, 24). Therefore, we 
consider here only the results for proteins identified in three of 
three biological replicates.
Tumor development is a multistep process that involves 
interrelated genetic, biological, and environmental factors. 
Tumorigenesis correlates with pathological phenotypes, clinical 
symptoms, and prognosis as well as proteomic changes (25). 
Numerous proteins were identified that are related to common 
biological processes such as immunity, hematopoiesis, inflamma-
tion, lipid metabolism, and cell differentiation. It is noteworthy 
that some proteins were excluded from analysis because of the 
possibility that they represent contaminants. Seven proteins were 
chosen for discussion, because they may be involved directly or 
indirectly in the development of breast cancer. Certain differen-
tially expressed proteins identified here were identified by other 
investigators, which supports the contribution of these proteins 
to the pathogenesis of breast cancer.
Proteomic analysis of Unbound-Pi 
Fractions
In the present study, we identified 2,106 proteins in the unbound-
PI fractions, which corresponded to proteins or glycoproteins 
with no detectable frutalin-affinity under the conditions used 
here. Because human blood plasma is rich in glycoproteins, 
frutalin-affinity chromatography was essential for reducing the 
complexity of plasma samples and significantly improved the 
overall dynamic range of protein detection, enabling the identifi-
cation of proteins present at very low concentrations.
Proteomics analysis revealed increased levels of plasma 
retinol-binding protein (Q5VY30_HUMAN) in the early stages 
FigUre 2 | results of nanoUPlc hDMse analysis showing (a) the peptide-match distribution to ascertain the quality of fragmentation and digestion; 
and (B) the distribution of fragment masses and the exact mass accuracy for the precursor ions ± 10 ppm.
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of breast cancer and slight differences in intermediate and 
advanced stages. This protein binds vitamin A and is the prin-
cipal and specific vitamin-A carrier in the blood. Some studies 
suggest that vitamin-A activity in cancer may be compromised 
at the level of retinol metabolism. Moreover, the interactions 
between retinoids and growth factors, such as transforming 
growth factor-β, are involved in regulating cell differentiation 
and proliferation (26, 27).
Oxidative stress occurs in many types of cancer cells and 
is associated with tumor cell proliferation (28). High levels 
FigUre 3 | Dynamic range. After identification and absolute quantitation of the proteins using yeast alcohol dehydrogenase (red) as internal standard, alpha-1-
antichymotrypsin (AACT_HUMAN) and alpha-1-antitrypsin (A1AT_HUMAN), represented by the blue and yellow spheres, respectively, were selected as 
housekeeping proteins used to normalize the data and perform label-free relative quantification of proteins present in the Unbound-PI and Bound-PII fractions, 
respectively.
TaBle 4 | Differentially expressed proteins identified in the plasma of patients with different stages of breast cancer compared with those of healthy 
subjects in the Unbound-Pi fraction.
Unbound-Pi fraction
accession Protein description score ratio expression
Breast cancer i × control
K2C1_HUMAN Keratin type II cytoskeletal 1 OS Homo sapiens 726.51 0.51 Down
APOC3_HUMAN Apolipoprotein C OS H. sapiens 2,621.36 1.51 Up
Q86TT1_HUMAN Full length cDNA clone CS0DD006YL02 of Neuroblastoma of H. sapiens 12,106.20 1.54 Up
Q5VY30_HUMAN Plasma retinol-binding protein 1 OS H. sapiens 1,483.52 1.55 Up
CPN2_HUMAN Carboxypeptidase N subunit 2 OS H. sapiens 145.72 1.58 Up
FIBB_HUMAN Fibrinogen beta chain OS H. sapiens 33,661.36 1.58 Up
CLUS_HUMAN Clusterin OS H. sapiens 12,211.18 1.63 Up
A1AG2_HUMAN Alpha-1-acid glycoprotein 2 OS H. sapiens 12,778.23 1.65 Up
PON1_HUMAN Serum paraoxonase arylesterase 1 OS H. sapiens 1,968.45 1.68 Up
APOA2_HUMAN Apolipoprotein-A-II OS H. sapiens 4,007.37 2.46 Up
Breast cancer ii × control
APOA2_HUMAN Apolipoprotein-A-II OS H. sapiens 4,007.37 1.51 Up
FIBB_HUMAN Fibrinogen beta chain OS H. sapiens 33,661.36 1.51 Up
CLUS_HUMAN Clusterin OS H. sapiens 12,211.18 1.70 Up
Breast cancer iii × control
FIBB_HUMAN Fibrinogen beta chain OS H. sapiens 33,661.36 1.55 Up
APOA2_HUMAN Apolipoprotein-A-II OS H. sapiens 4,007.37 2.27 Up
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TaBle 5 | Differentially expressed proteins identified in the plasma of patients with different stages of breast cancer compared with those of healthy 
subjects in the Bound-Pii fraction.
Bound-Pii fraction
accession Protein description score ratio expression
Breast cancer i × control
Q6N092_HUMAN Putative uncharacterized protein DKFZp686K18196 fragment OS Homo sapiens 36,802.04 0.41 Down
Q9NPP6_HUMAN Immunoglobulin heavy chain variant fragment OS H. sapiens 17,866.64 0.53 Down
Q8NEJ1_HUMAN Uncharacterized protein OS H. sapiens 86,719.59 0.60 Down
F5GXS0_HUMAN C4b B OS H. sapiens 41,296.95 0.64 Down
CLUS_HUMAN Clusterin OS H. sapiens 1,846.24 1.57 Up
APOC3_HUMAN Apolipoprotein C III OS H. sapiens 4,164.40 1.68 Up
Q567P1_HUMAN IGL protein OS H. sapiens 85,322.29 1.92 Up
Q6GMX0_HUMAN Uncharacterized protein OS H. sapiens 130,309.10 3.03 Up
Breast cancer ii × control
Q6N092_HUMAN Putative uncharacterized protein DKFZp686K18196 fragment OS H. sapiens 36,802.04 0.27 Down
Q9NPP6_HUMAN Immunoglobulin heavy chain variant fragment OS H. sapiens 17,866.64 0.52 Down
B7ZLE5_HUMAN FN1 protein OS H. sapiens 14,423.90 0.55 Down
F5GXS0_HUMAN C4b B OS H. sapiens 41,296.95 0.59 Down
KV116_HUMAN Ig kappa chain V I region Roy OS H. sapiens 6,105.97 0.63 Down
CLUS_HUMAN Clusterin OS H. sapiens 1,846.24 1.60 Up
APOC3_HUMAN Apolipoprotein C III OS H. sapiens 4,164.40 1.62 Up
Q567P1_HUMAN IGL protein OS H. sapiens 85,322.29 1.84 Up
Q6GMX0_HUMAN Uncharacterized protein OS H. sapiens 130,309.10 2.56 Up
Breast cancer iii × control
Q9HCC1_HUMAN Single chain Fv fragment OS H. sapiens 7,583.12 0.35 Down
Q9NPP6_HUMAN Immunoglobulin heavy chain variant fragment OS H. sapiens 17,866.64 0.48 Down
Q6P089_HUMAN IGH protein OS H. sapiens 16,000.74 0.49 Down
Q6N092_HUMAN Putative uncharacterized protein DKFZp686K18196 fragment OS H. sapiens 36,802.04 0.50 Down
Q8NCL6_HUMAN cDNA FLJ90170 fis clone MAMMA1000370 highly similar to Ig alpha 1 chain C region OS 
H. sapiens
36,698.85 0.58 Down
F5GXS0_HUMAN C4b B OS H. sapiens 41,296.95 0.59 Down
Q6MZQ6_HUMAN Putative uncharacterized protein DKFZp686G11190 OS H. sapiens 2,964.75 1.63 Up
Q6GMX0_HUMAN Uncharacterized protein OS H. sapiens 130,309.10 2.64 Up
8
Lobo et al. Stage-Specific Protein Expression in Breast Cancer
Frontiers in Oncology | www.frontiersin.org February 2017 | Volume 7 | Article 14
of serum paraoxonase/arylesterase (PON1_HUMAN) were 
detected mainly in samples from the early stage of breast 
cancer. Lipid peroxidation characterizes oxidative damage 
to cell membranes, lipoproteins, and other lipid-containing 
structures. Overproduction of lipid peroxidation byproducts 
and alterations in the antioxidant defense system as well as 
serum paraoxonase and arylesterase activities are implicated 
in the pathogenesis of cancer (29, 30). Thus, the serum 
paraoxonase/arylesterase found “upregulated” in the present 
analysis may be a biological attempt to increase the clearance 
of lipid peroxidation products, thereby decreasing oxidative 
stress.
A high level of alpha-1-acid glycoprotein (A1AG2_HUMAN) 
was identified here in the early stage of breast cancer, and its level 
was slightly increased in the intermediate stage of breast cancer. 
Alpha-1-acid-glycoprotein is a plasma acute-phase glycoprotein 
with a high proportion of glycosylated amino acid residues. 
Although we found here that the levels of AAG were 1.65-fold 
higher in the plasma of women with breast cancer compared 
with those of healthy women, the mean plasma AAG increased to 
concentrations in breast, lung, and ovarian cancers are two-times 
higher compared with those of healthy people (31). Further, the 
concentrations of AAG increase to 5-fold greater than baseline 
in various acute-phase responses such as inflammation, stress, 
pregnancy, and myocardial infarction (32).
High levels of apolipoprotein A-II (APOA2_HUMAN) 
were detected here that were elevated significantly in the early 
and advanced stages of the disease. Lipid synthesis, which is an 
integrated outcome of genetic, epigenetic, and environmental 
factors, promotes the growth and survival of cancer cells. Certain 
apolipoproteins play a central role in lipid metabolism, and 
changes in the expression of ApoA2 occur in malignancies other 
than breast cancer (33, 34). Podzielinski et al. (35) suggested that 
lipoprotein metabolism is deregulated in ovarian cancer and that 
ApoA2 warrants further investigation as a marker for ovarian 
tumors. Moreover, there is an association between obesity and 
breast cancer. The tumor microenvironment, particularly that of 
adipose tissue, and breast cancer development seem to have an 
intricate relationship (36, 37).
Proteomic analysis of the Bound-Pii 
Fraction
Posttranslational modifications of proteins such as glycosylation, 
phosphorylation, and ubiquitination play important roles in the 
genesis and development of cancer (25). Glycosylation is a major 
modification that affects charge, conformation, and stability and 
FigUre 4 | continued
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FigUre 4 | continued 
ratios of the levels of representative proteins [Q5VY30_hUMan—plasma retinol-binding protein; POn1_hUMan—serum paraoxonase arylesterase; 
a1ag2_hUMan—alpha-1-acid glycoprotein; aPOa2_hUMan—apolipoprotein-a-ii; clUs_hUMan—clusterin; aPOc3_hUMan—apolipoprotein c iii; 
and F5gXs0_hUMan—c4b B, detected in unbound-Pi (a) and bound-Pii fractions (B) of breast cancer patients and healthy controls]. The different 
breast cancer stages are represented as follows: light gray (I—early), dark gray (II—intermediate), and black (III—advanced).
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plays a crucial role in processes, such as cell recognition, cell–cell 
signaling, embryonic development, and binding of hormones 
and toxins (38). Changes in the glycosylation of proteins are 
important in many biological processes, and aberrant protein 
glycosylation is associated with cancer development (4). The 
abnormal glycosylation of proteins correlates with various dis-
eases including cancer. Glycosylated proteins are useful targets 
for the development of new vaccines and are used as biomarkers 
for the early detection and diagnosis of disease (39).
Apolipoprotein C-III (APOC3_HUMAN) was detected in 
unbound-PI and bound-PII fractions. The level of ApoC3 was 
slightly increased only in the early stage of breast cancer compared 
with that in the unbound-PI fraction (1.51 breast cancer:control 
ratio) and was present in elevated levels in the bound-PII fractions 
from patients with early and intermediate stages of breast cancer. 
ApoC3 consists of a very low-density lipoprotein that is synthe-
sized in the liver and intestine. A high level of ApoC3 correlates 
with hypertriglyceridemia and is often associated with coronary 
heart disease and atherosclerosis (40, 41). ApoC3 is glycosylated 
at threonine-74, and there are three protein glycoforms (42) that 
share mucin-type core-1 O-glycosylation (galactose β1−3 glycan) 
linked to an N-acetylgalactosamine residue (Galβ1−3GalNAc). 
Two of these three isoforms occur with a modified glycan with 
either one or two sialic acid residues [Galβ1−3(NeuAcα2−6)
GalNAc and NeuAcα2−3Galβ1−3(NeuAcα2−6)GalNAc] (42, 
43). Moreover, ApoC3 is extensively studied for potential use as a 
biomarker of disease, because changes in the ratio of its different 
glyco-isoforms occur in obesity, kidney disease, liver disease, and 
sepsis (44). However, there is no published information indicat-
ing an association of ApoC3 with breast cancer.
ApoC3 was differentially expressed mainly in the bound-
PII fraction. ApoC3 binds reversibly to frutalin, a tetrameric 
lectin, which binds α-d-galactose residues and to complex 
carbohydrates containing Galα1-3 glycans (18, 45–47). ApoC3 
is glycosylated mainly with Galβ1-3 glycans, and we show here 
that is was overexpressed in breast cancer patients compared with 
healthy controls, suggesting a change in the glycosylation pattern 
of ApoC3. ApoC3 is differentially glycosylated (galactose β1−3 
to galactose α1−3 residues) during tumorigenesis. Nevertheless, 
such a possible change in glycosylation is most intriguing and 
supports the hypothesis that there is interplay between the 
changes in the glycosylation machinery and breast tumor biology.
The levels of clusterin (CLUS_HUMAN) were increased in 
the plasma of patients with breast cancer. In contrast to ApoC3, 
CLUS levels were higher in unbound-PI and bound-PII fractions 
at stages I and II. CLUS is an extracellular chaperone implicated 
in DNA repair, cell-cycle regulation, apoptotic cell death, and 
tumorigenesis (48). It is heavily glycosylated, and nearly 25% of 
its mass comprises different N-linked glycans (49), which may 
explain its presence in both fractions. Clusterin expression is 
altered in different cancers, including overexpression in human 
breast carcinoma (50–52), which is associated with increased 
tumor size, progesterone receptor-negative status, and the pro-
gression from primary to metastatic carcinoma in lymph nodes 
(53). The silencing of clusterin expression using small interfering 
RNAs decreases the invasion and migration of breast cancer 
cells and inhibits cell growth and metastatic progression in an 
orthotopic model, indicating that clusterin may contribute to the 
local growth-inhibitory effects in the microenvironment of the 
breast tumor (54).
Finally, decreased levels of C4b_B (F5GXS0_HUMAN) were 
detected in bound-PII fractions in all stages of breast cancer. 
Although some studies discuss the relationship of the inflam-
matory process in the immune microenvironment of tumors, 
few reports establish the influence of the protein components 
of the complement cascade in tumorigenesis. The complement 
system plays an important role in innate immunity and immunity 
to tumors. Rutkowski et  al. (55) concluded that complement 
proteins may promote carcinogenesis; facilitate the deregulation 
of mitogenic signaling pathways; stimulate angiogenesis; induce 
resistance to apoptosis; sustain cellular proliferation, invasion, 
and metastasis; and allow tumor cells to escape from immuno-
surveillance. These possibilities raise a new view of the role of the 
complement system in cancer.
cOnclUsiOn
In summary, our study employed a proteomic approach that 
included a frutalin lectin-affinity chromatography and data-
independent (MSE) label-free mass spectrometry analysis that 
could serve as experimental design for the initial stage of studies 
in breast cancer proteomics research. Additionally we used an 
easily obtained material, such as plasma, rather than clinical 
samples such as tissue, often difficult to obtain.
We show here that proteins from unbound and bound frac-
tions using lectin-affinity chromatography were present at dif-
ferent levels in plasma from patients with breast cancer at three 
different stages compared with those of healthy control subjects. 
The proteins plasma retinol-binding protein, serum paraoxonase/
arylesterase, alpha-1-acid glycoprotein, apolipoprotein A-II, 
apolipoprotein C-III, clusterin, and C4b_B were differentially 
expressed. Interestingly, a few of the proteins that we identified 
were also observed in other studies, suggesting that this general 
approach is reproducible. However, until now there is no pub-
lished information indicating an association of apolipoprotein 
C-III with breast cancer. Since the disease might be associated 
with a change in the amount of a protein but also in the structure 
11
Lobo et al. Stage-Specific Protein Expression in Breast Cancer
Frontiers in Oncology | www.frontiersin.org February 2017 | Volume 7 | Article 14
of a given posttranslational modification, such as glycosylation, 
our strategy represents a potentially valuable approach for the 
discovery of new protein targets in breast cancer.
Accordingly, our method yielded a list of proteins for sub-
sequent investigation. Finally, the differential expression data 
presented here contribute to the development of a profile or a 
panel of certain proteins that suggest an association with the 
development and characterization of breast cancer at different 
stages.
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